Yale School of Public Health, working with the Connecticut Department of Public Health, will monitor the early impact of a vaccine against the most common sexually transmitted disease in the United States and the leading cause of cervical cancer—human papillomavirus virus (HPV).
More than 20 million people are currently infected with the virus, and 6.2 million new infections are diagnosed each year. Most HPV infections are cleared by the immune system, but some persist, causing pre-cancerous lesions known as CIN2/3 and, ultimately, cervical cancer. Half of the more than 30 known sexually transmitted strains of HPV are considered high-risk types linked to cervical cancer.
Cervical Cancer - Incidence
Cervical cancer is the second most common cancer among women and is the primary cause of cancer-related deaths in developing countries
Advertisement
The vaccine GARDASIL™ was licensed for females nine-to-26 years old to prevent HPV-related cervical cancer, cervical, vaginal, and vulvar cancer precursors, and anogenital warts. The vaccine targets the strains HPV16 and HPV18 that are thought to cause 70 percent of cervical cancers. It also targets strains HPV6 and HPV11 that cause 90 percent of genital warts.
To monitor the early impact of the HPV vaccine, the Yale office of the Connecticut Emerging Infections Program will survey pathology laboratories and health care providers for information about new CIN2/3 diagnoses among women in New Haven County. The goal is to determine whether there has been a decrease of new diagnoses since the introduction of the vaccine.
![FDA Grants Standard Review for GSK's Experimental HPV Vaccine Cervarix]( "FDA Grants Standard Review for GSK's Experimental HPV Vaccine Cervarix")
GlaxoSmithKline on Thursday announced that FDA has granted a standard 10-month review of its experimental human papillomavirus vaccine Cervarix
"We expect to see the greatest impact among young women, but over time we also expect to see effects for women over 26 who were vaccinated at a younger age," said Linda Niccolai, assistant professor and director of the project under the emerging infections program Niccolai said. "Also, there will presumably be less transmission to male partners, who can re-infect their partners."
Niccolai notes that if it can be shown there are fewer pre-cancerous lesions due to vaccination, the vaccine might be made more widely available.
"Perhaps structural and financial policy changes also will be made to increase accessibility for those who want the vaccine," said Niccolai.
This work is supported by the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. The CDC, which reports 9,710 new cases of cervical cancer each year leading to some 3,700 deaths, has selected four monitoring sites in four states—California, New York, Tennesee, and Connecticut.
James Meek, associate director of the emerging infections program, said another goal is to watch for possible changes in the strain of the virus responsible for the pre-cancerous lesions.
"As vaccine use increases, we expect to see a decrease in the occurrence of lesions caused by HPV strains 16 or 18," he said. "It will be important to know if other less common cancer-causing strains of HPV, such as HPV33 or HPV45, become more common."
Source: YALE University
LIN/P
FDA Grants Standard Review for GSK's Experimental HPV Vaccine Cervarix
GlaxoSmithKline on Thursday announced that FDA has granted a standard 10-month review of its experimental human papillomavirus vaccine Cervarix
Advertisement
"We expect to see the greatest impact among young women, but over time we also expect to see effects for women over 26 who were vaccinated at a younger age," said Linda Niccolai, assistant professor and director of the project under the emerging infections program Niccolai said. "Also, there will presumably be less transmission to male partners, who can re-infect their partners."
Niccolai notes that if it can be shown there are fewer pre-cancerous lesions due to vaccination, the vaccine might be made more widely available.
"Perhaps structural and financial policy changes also will be made to increase accessibility for those who want the vaccine," said Niccolai.
This work is supported by the Centers for Disease Control and Prevention (CDC) in Atlanta, Ga. The CDC, which reports 9,710 new cases of cervical cancer each year leading to some 3,700 deaths, has selected four monitoring sites in four states—California, New York, Tennesee, and Connecticut.
James Meek, associate director of the emerging infections program, said another goal is to watch for possible changes in the strain of the virus responsible for the pre-cancerous lesions.
"As vaccine use increases, we expect to see a decrease in the occurrence of lesions caused by HPV strains 16 or 18," he said. "It will be important to know if other less common cancer-causing strains of HPV, such as HPV33 or HPV45, become more common."
Source: YALE University
LIN/P
HPV Vaccine Won't Fight Existing Infections
A new study has found that the human papillomavirus (HPV) vaccine is not effective in preventing the spread of the virus in women who are already infected.
Advertisement
 Teenage Girls With STD Might Be Predisposed to CancerTen percent of girls, under the age of 16, who are infected with sexually transmitted disease (STD) might be predisposed to cervical cancer later in life says a new study in UK. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The impact of anti-obesity drugs on survival rates among osteoarthritis patients is under scrutiny, evaluating their potential influence on mortality risks.
Researchers create needle-free Zika vaccine patch, using HD-MAP tech, aiming to protect against fatal virus spread by mosquitoes.
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.